A life science and deeptech fund unlocking the power of the endocannabinoid system
ÓSKARE CAPITAL, has launched the first AIFM and ESG compatible Venture Capital fund with an investment focus on innovative companies and teams in Europe working on novel therapeutics (cannabinoids and other molecules) that target the endocannabinoid system as well as the ‘picks and shovels’ of the associated ecosystem of services and products that support this fast-growing global market.
We are the first fund taking this approach and have a unique pipeline of deals. The Fund will invest in startups across the entire value chain (from Seed to Patient) but will not invest in cannabis production or recreational cannabis.
With a highly favorable legal and regulatory landscape in Europe, medical cannabis is a high growth market (€15 B in 2029) and will continue to disrupt the wider market of diseases addressable via the Endocannabinoid System (€438 B today)
Promising new cannabinoid solutions under study for epilepsy, pain, spasticity, anxiety, and sleep oncology, cardiovascular conditions, Autism and Down's Syndrome among others
Óskare Capital has identified a large number of companies in its dealflow pipeline with strong teams, disruptive IP and scalable technologies
Óskare Fund 1 | €150 M target | AIFM domiciled in Dublin, Ireland (ICAV) | Spin-off to Series B + | European focus, global remit
The MEDCAN Fund | £10 M target | SEIS and EIS fund, in partnership with Sapphire Capital | UK focus
Management team based in Paris, London and New York
ESG compliant and will not invest in recreational cannabis or cannabis production
Investments in science, services and solutions with high barriers to entry
Focus on scientific innovation and in generating solutions and tangible outcomes in the wellness and medical sectors for which there is strong scientific rationale to utilize cannabinoids
The fund will prioritize opportunities that are protected by strong intellectual property